1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 1: Summary of the imaging parameters pre- and postbevacizumab
Parameter Prebevacizumab Mean (SD) × 103 Postbevacizumab Mean (SD) × 103 P Value (T Value) EC100% 2.52 (0.57) 2.43 (0.57) .256 (1.15) EC75% 1.91 (0.53) 1.77 (0.47) .281 (1.08) EC50% 1.51 (0.48) 1.38 (0.40) .277 (1.11) EC25% 1.06 (0.38) 0.98 (0.30) .184 (1.35) FLAIRVOLa 121.88 (70.68) 77.317 (38.55) .002 (4.28) CEVOLa 24.90 (15.26) 9.16 (9.17) <.001 (6.34)
↵a P < .05.